乳腺癌细胞原位移植模型的建立及紫杉醇和表柔比星联合用药疗效  

Establishment of an orthotopic transplantation model of breast cancer cells and observation of the treatment of paclitaxel combined with epirubicin

作　　者：李婕 黄文革[2] 刘宝宁 郭芬芬[2] LI Jie;HUANG Wenge;LIU Baoning;GUO Fenfen(Guangdong Second Provincial General Hospital,Guangzhou,Guangdong 510317,China)

机构地区：[1]广东省第二人民医院,广东广州510317 [2]中山大学实验动物中心,广东广州510080

出　　处：《中国热带医学》2018年第8期766-769,共4页China Tropical Medicine

基　　金：广东省科技计划项目(No.2016A030303007)

摘　　要：目的建立乳腺癌细胞原位移植瘤模型,观察紫杉醇及联合表柔比星的抑瘤效果,为临床联合用药提供实验依据。方法用乳腺癌细胞悬液接种于动物脂肪垫下建立荷瘤鼠,待瘤块直径≥1 cm时,处死动物剥离肿瘤,接种于裸小鼠脂肪垫下,建立原位移植的乳腺癌肿瘤模型。成模动物按瘤体积大小随机分为紫杉醇组、表柔比星组、联合用药组及模型对照组4组,连续给药3周后,观察各组小鼠的肿瘤生长情况,抑瘤率及肿瘤组织中P53蛋白的表达情况。结果成功建立原位移植的乳腺癌肿瘤模型,成模小鼠给药3周后,与模型对照组相比,各给药组小鼠体重和瘤重均有显著下降(P<0.05),其中,紫杉醇组抑瘤效果显著;给药后第8天,紫杉醇组小鼠肿瘤体积与模型对照组比较有显著性差异(P<0.05),给药后第21天,紫杉醇组的抑瘤率达到82.53%;肿瘤组织中P53蛋白的表达情况,与模型对照组相比,紫杉醇组和联合给药组表达显著减弱(P<0.05)。结论成功构建原位乳腺癌模型,实验结果显示紫杉醇及其与表柔比星的联合用药对肿瘤均有一定抑制作用。Objective To establish an orthotopic implantation model of breast cancer cells, observe the effect of paclitaxel combined with epirubicin on tumor and provide experimental evidence for clinical therapy. Methods The breast cancer cell was suspended in serum free medium and injected into the second mammary fat pad to establish tumor-bearing mice which were sacrificed till the diameter of the tumor equal to or larger than 1 cm. The tumor tissues of the tumor-bearing mice were inoculated into the fat pads of the nude mice to establish orthotopic transplantation model. The model animals were randomly divided into paclitaxel, epirubicin, combination group and model control group. After 3 weeks of administration, the growth of tumor, the rate of tumor inhibition and the expression of P53 protein in tumor tissues were observed. Results The orthotopic transplantation model of breast cancer cells was established successfully. After 3 weeks of administration, compared with the model control group, the body weight and tumor weight of each treatment group was significantly decreased（P〈0.05）,the antitumor effect of paclitaxel group was significant. On the 8th day after administration, compared with the model control group, the tumor volume of paclitaxel group mice was significantly reducedP〈0.05）. On the 21st day after administration, the tumor inhibition rate of the paclitaxel group was 82.53%. Furthermore, the expression of P53 protein in tumor tissues was significantly decreased compared with the model control group（P〈0.05）. Conclusions The model of breast cancer in situ was successfully established. The experimental results showed that the combination of paclitaxel and epirubicin had a certain inhibitory effect on the tumor.

关 键 词：乳腺癌 原位移植模型 紫杉醇 表柔比星 

分 类 号：R737.9[医药卫生—肿瘤]